Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine

Patricia Gómez De León, F. Javier Díaz García, Jose Luis Arredondo, Jorge Segura, Silvia Giono Cerezo, Jose I. Santos

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Background: In 1999 H. influenzae b (Hib) PRP-T vaccine was introduced into primary immunization schedule in Mexico. There have been no studies evaluating antibody response after widespread immunization in our country. It is now recognized that Hib conjugates induce significant initial antibody levels that in some cases wane over time. This study relies on the measurement of IgG serum antibody concentrations to Hib capsular polysaccharide (PS) and is interpreted in the light of the accepted levels ≥0.15 μg/mL for short-term protection against Hib invasive disease and ≥5.0 μg/mL for protection against Hib oropharyngeal carriage. Methods: Using a validated ELISA assay, we measured the IgG serum antibody concentrations in 115 children between 7 and 93 months of age who had received three doses of PRP-T. We used the standard reference serum US FDA 1983 for quantification of PS antibody levels. Concentrations were estimated using 3 rd degree polynomial regression lines. As there was no unvaccinated group available (>95% of Mexican children have received the Hib vaccine), the study was designed as a cross-sectional. Results: All children had serum IgG concentrations ≥0.15 μg/mL [range 0.24-54.64 μg/mL]; 69.6 % (80/115) had ≥1.0 μg/mL and 14% (16/115) showed concentrations ≥5.0 μg/mL. The vaccine elicited geometric mean concentrations (GMC) of 4.0, 1.6, 1.4 and 2.4 μg/mL in groups of 7-12, 13-24, 25-48 and 49-93 month-old respectively. Conclusions: PRP-T vaccination in this group of Mexican children has resulted in serum IgG concentrations ≥0.15 μg/mL, suggesting that Hib immunization has conferred protection against invasive disease. ©2007 Landes Bioscience.
Original languageAmerican English
Pages (from-to)187-191
Number of pages167
JournalHuman Vaccines
DOIs
StatePublished - 1 Jan 2007

Fingerprint

Haemophilus influenzae type b
Polysaccharides
Vaccines
Immunoglobulin G
Serum
Antibodies
Immunization
Haemophilus Vaccines
Immunization Schedule
Mexico
Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate
Antibody Formation
Vaccination
Enzyme-Linked Immunosorbent Assay

Cite this

De León, Patricia Gómez ; García, F. Javier Díaz ; Arredondo, Jose Luis ; Segura, Jorge ; Cerezo, Silvia Giono ; Santos, Jose I. / Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine. In: Human Vaccines. 2007 ; pp. 187-191.
@article{0ce1f3c6448a4bd0bbb77ee88d801479,
title = "Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine",
abstract = "Background: In 1999 H. influenzae b (Hib) PRP-T vaccine was introduced into primary immunization schedule in Mexico. There have been no studies evaluating antibody response after widespread immunization in our country. It is now recognized that Hib conjugates induce significant initial antibody levels that in some cases wane over time. This study relies on the measurement of IgG serum antibody concentrations to Hib capsular polysaccharide (PS) and is interpreted in the light of the accepted levels ≥0.15 μg/mL for short-term protection against Hib invasive disease and ≥5.0 μg/mL for protection against Hib oropharyngeal carriage. Methods: Using a validated ELISA assay, we measured the IgG serum antibody concentrations in 115 children between 7 and 93 months of age who had received three doses of PRP-T. We used the standard reference serum US FDA 1983 for quantification of PS antibody levels. Concentrations were estimated using 3 rd degree polynomial regression lines. As there was no unvaccinated group available (>95{\%} of Mexican children have received the Hib vaccine), the study was designed as a cross-sectional. Results: All children had serum IgG concentrations ≥0.15 μg/mL [range 0.24-54.64 μg/mL]; 69.6 {\%} (80/115) had ≥1.0 μg/mL and 14{\%} (16/115) showed concentrations ≥5.0 μg/mL. The vaccine elicited geometric mean concentrations (GMC) of 4.0, 1.6, 1.4 and 2.4 μg/mL in groups of 7-12, 13-24, 25-48 and 49-93 month-old respectively. Conclusions: PRP-T vaccination in this group of Mexican children has resulted in serum IgG concentrations ≥0.15 μg/mL, suggesting that Hib immunization has conferred protection against invasive disease. {\circledC}2007 Landes Bioscience.",
author = "{De Le{\'o}n}, {Patricia G{\'o}mez} and Garc{\'i}a, {F. Javier D{\'i}az} and Arredondo, {Jose Luis} and Jorge Segura and Cerezo, {Silvia Giono} and Santos, {Jose I.}",
year = "2007",
month = "1",
day = "1",
doi = "10.4161/hv.3.5.4376",
language = "American English",
pages = "187--191",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",

}

Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine. / De León, Patricia Gómez; García, F. Javier Díaz; Arredondo, Jose Luis; Segura, Jorge; Cerezo, Silvia Giono; Santos, Jose I.

In: Human Vaccines, 01.01.2007, p. 187-191.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Anticapsular polysaccharide IgG concentrations in Mexican children formerly immunized with Haemophilus influenzae b PRP-T vaccine

AU - De León, Patricia Gómez

AU - García, F. Javier Díaz

AU - Arredondo, Jose Luis

AU - Segura, Jorge

AU - Cerezo, Silvia Giono

AU - Santos, Jose I.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: In 1999 H. influenzae b (Hib) PRP-T vaccine was introduced into primary immunization schedule in Mexico. There have been no studies evaluating antibody response after widespread immunization in our country. It is now recognized that Hib conjugates induce significant initial antibody levels that in some cases wane over time. This study relies on the measurement of IgG serum antibody concentrations to Hib capsular polysaccharide (PS) and is interpreted in the light of the accepted levels ≥0.15 μg/mL for short-term protection against Hib invasive disease and ≥5.0 μg/mL for protection against Hib oropharyngeal carriage. Methods: Using a validated ELISA assay, we measured the IgG serum antibody concentrations in 115 children between 7 and 93 months of age who had received three doses of PRP-T. We used the standard reference serum US FDA 1983 for quantification of PS antibody levels. Concentrations were estimated using 3 rd degree polynomial regression lines. As there was no unvaccinated group available (>95% of Mexican children have received the Hib vaccine), the study was designed as a cross-sectional. Results: All children had serum IgG concentrations ≥0.15 μg/mL [range 0.24-54.64 μg/mL]; 69.6 % (80/115) had ≥1.0 μg/mL and 14% (16/115) showed concentrations ≥5.0 μg/mL. The vaccine elicited geometric mean concentrations (GMC) of 4.0, 1.6, 1.4 and 2.4 μg/mL in groups of 7-12, 13-24, 25-48 and 49-93 month-old respectively. Conclusions: PRP-T vaccination in this group of Mexican children has resulted in serum IgG concentrations ≥0.15 μg/mL, suggesting that Hib immunization has conferred protection against invasive disease. ©2007 Landes Bioscience.

AB - Background: In 1999 H. influenzae b (Hib) PRP-T vaccine was introduced into primary immunization schedule in Mexico. There have been no studies evaluating antibody response after widespread immunization in our country. It is now recognized that Hib conjugates induce significant initial antibody levels that in some cases wane over time. This study relies on the measurement of IgG serum antibody concentrations to Hib capsular polysaccharide (PS) and is interpreted in the light of the accepted levels ≥0.15 μg/mL for short-term protection against Hib invasive disease and ≥5.0 μg/mL for protection against Hib oropharyngeal carriage. Methods: Using a validated ELISA assay, we measured the IgG serum antibody concentrations in 115 children between 7 and 93 months of age who had received three doses of PRP-T. We used the standard reference serum US FDA 1983 for quantification of PS antibody levels. Concentrations were estimated using 3 rd degree polynomial regression lines. As there was no unvaccinated group available (>95% of Mexican children have received the Hib vaccine), the study was designed as a cross-sectional. Results: All children had serum IgG concentrations ≥0.15 μg/mL [range 0.24-54.64 μg/mL]; 69.6 % (80/115) had ≥1.0 μg/mL and 14% (16/115) showed concentrations ≥5.0 μg/mL. The vaccine elicited geometric mean concentrations (GMC) of 4.0, 1.6, 1.4 and 2.4 μg/mL in groups of 7-12, 13-24, 25-48 and 49-93 month-old respectively. Conclusions: PRP-T vaccination in this group of Mexican children has resulted in serum IgG concentrations ≥0.15 μg/mL, suggesting that Hib immunization has conferred protection against invasive disease. ©2007 Landes Bioscience.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35349011568&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=35349011568&origin=inward

U2 - 10.4161/hv.3.5.4376

DO - 10.4161/hv.3.5.4376

M3 - Article

SP - 187

EP - 191

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

ER -